Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite (HDM) Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* history of HDM rhinitis allergy for \> 1 year~* sensitized to D. pteronyssinus and/or D. farinae~* RTSS \>= 6 at least 2 time points during allergen challenge session~Exclusion Criteria:~* co sensitization to other allergen than HDM~* FEV1 \< 80%~* Asthma GINA \> 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 100IR (Type: EXPERIMENTAL): None
- 300IR (Type: EXPERIMENTAL): None
- 500IR (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).